P J Blanchet < P J Bédard < P J Devereaux

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 36.
[0-20] [0 - 20][0 - 36][20-35][20-40]

Ident.	Authors (with country if any)	Title
003151 (2003)	A. Hadj Tahar [Canada] ; R. Grondin ; L. Grégoire ; F. Calon ; T. Di Paolo ; P J Bédard	New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
003860 (2000)	M. Goulet [Canada] ; R. Grondin ; M. Morissette ; S. Maltais ; P. Falardeau ; P J Bédard ; T. Di Paolo	Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-monkeys.
003866 (2000)	R. Grondin [Canada] ; A. Hadj Tahar ; V D Doan ; P. Ladure ; P J Bédard	Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys.
003875 (2000)	F. Calon [Canada] ; R. Grondin ; M. Morissette ; M. Goulet ; P J Blanchet ; T. Di Paolo ; P J Bédard	Molecular basis of levodopa-induced dyskinesias.
003B98 (1999)	R. Grondin [Canada] ; V D Doan ; L. Grégoire ; P J Bédard	D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys.
003C02 (1999)	R. Grondin [Canada] ; P J Bédard ; A. Hadj Tahar ; L. Grégoire ; A. Mori ; H. Kase	Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.
003E31 (1998)	A. Hadj Tahar [Canada] ; P J Bédard	[Understanding and treating levodopa-induced dyskinesias].
003E80 (1998)	M. Morissette ; M. Goulet ; R. Grondin ; P. Blanchet ; P J Bédard ; T. Di Paolo ; D. Lévesque	Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies.
004093 (1997)	J. Doyon [Canada] ; D. Gaudreau ; R. Laforce ; M. Castonguay ; P J Bédard ; F. Bédard ; J P Bouchard	Role of the striatum, cerebellum, and frontal lobes in the learning of a visuomotor sequence.
004097 (1997)	M. Morissette [Canada] ; M. Goulet ; J J Soghomonian ; P J Blanchet ; F. Calon ; P J Bédard ; T. Di Paolo	Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.
004098 (1997)	R. Grondin [Canada] ; P J Bédard ; D R Britton ; K. Shiosaki	Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
004348 (1996)	P J Blanchet [Canada] ; P. Allard ; L. Grégoire ; F. Tardif ; P J Bédard	Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients.
004370 (1996)	M. Goulet [Canada] ; R. Grondin ; P J Blanchet ; P J Bédard ; T. Di Paolo	Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
004373 (1996)	P J Blanchet [Canada] ; R. Grondin ; P J Bédard ; K. Shiosaki ; D R Britton	Dopamine D1 receptor desensitization profile in MPTP-lesioned primates.
004625 (1995)	F. Calon [Canada] ; M. Goulet ; P J Blanchet ; J C Martel ; M F Piercey ; P J Bédard ; T. Di Paolo	Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
004633 (1995)	C. Gagnon [Canada] ; B. Gomez-Mancilla ; R. Markstein ; P J Bédard ; T. Di Paolo	Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors.
004870 (1994)	P J Blanchet [Canada] ; R. Boucher ; P J Bédard	Excitotoxic lateral pallidotomy does not relieve L-dopa-induced dyskinesia in MPTP parkinsonian monkeys.
004A88 (1993)	P J Bédard [Canada] ; B. Gomez-Mancilla ; P. Blanchette ; C. Gagnon ; P. Falardeau ; T. Dipaolo	Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
004B09 (1993)	B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P J Bédard	Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors.
004B11 (1993)	P. Blanchet [Canada] ; P J Bédard ; D R Britton ; J W Kebabian	Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
004B14 (1993)	C. Gagnon [Canada] ; B. Gomez-Mancilla ; P J Bédard ; T. Di Paolo	Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Merge

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/Author.i -k "P J Bédard" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/Author.i  \
                -Sk "P J Bédard" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Merge
   |type=    indexItem
   |index=    Author.i
   |clé=    P J Bédard
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022